The objective of this project was to create a siRNA-combined advanced therapy, which will allow a more personalised treatment for the different stages of osteoarthritis in order to get to develop an efficient therapy to improve the quality of life of those affected by osteoarthritis, a chronic joint condition that affects more and more people every year.
On 13 October, our expert Christopher Mann joined the inaugural Swiss Cell & Gene Summit, organised by
Asphalion experts Jon Giblin and Christopher Mann, together with experts from the ARDAT Consortium, have just published
After four years of research into Polyendocrine Metabolic Ovarian Syndrome (PMOS) (previously known as polycystic ovary syndrome
Biosimilars are biological medicines that are highly similar in structure, biological activity, safety, and effectiveness to an
NAMs are innovative testing methods and strategies used to assess the safety, efficacy, and quality of drugs
Developing therapies for rare diseases requires more than scientific innovation. It demands a robust regulatory strategy supported by high-quality medical and scientific documentation.
Search or filter
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
